Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences

---

Atıf İçin Kopyala

Ormeci N., Sezgin O., Karaali R., AYGEN B., Turan D., Yaras S., ...Daha Fazla

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.31, sa.4, ss.534-539, 2019 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 31 Sayı: 4
• Basım Tarihi: 2019
• Doi Numarası: 10.1097/meg.0000000000001334
• Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.534-539
• Erciyes Üniversitesi Adresli: Evet

Özet

Introduction Both hepatitis C virus infection (HCV) and chronic kidney disease (CKD) have been comorbid illnesses with increasing morbidity and mortality. The present study was conducted to present real-life experiences about treatment of HCV and CKD with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day, the PROD regimen.